Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Key Inclusion Criteria:

* Histologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative chemotherapy measures do not exist or are no longer effective
* Age \> 18 years old
* ECOG Performance Status \< 2
* Female patients may not be pregnant or lactating and must be willing to practice contraception
* Adequate organ function as defined by the following:

  * Serum creatinine \< 1.5 mg/dl
  * Absolute neutrophil count (ANC) \> 1500/dL
  * Platelets \> 100,000/dL
  * Total bilirubin \< upper limit of normal (ULN) for the reference lab
  * AST, ALT, and alkaline phosphatase must be within the designated range allowing for eligibility

Key Exclusion Criteria:

* Other chemotherapy treatment \< 4 weeks prior to enrollment Treatment with capecitabine, 5-fluorouracil (5-FU), or a platinum agent \< 3 months from time of enrollment
* Radiotherapy involving \> 30% of the active bone marrow
* Radiotherapy \< 4 weeks prior to enrollment
* Pre-existing peripheral neuropathy \> grade 1
* Pre-existing hearing loss \> grade 2
* Metastatic brain or meningeal tumors unless the patient is \> 6 months from definitive therapy, had a negative imaging study within 4 weeks of study entry, is clinically stable with respect to the tumor at the time of study entry, and is not receiving steroid therapy or taper
* Patients who have not recovered (\> grade 1) from the following toxicities of previous regimens before enrollment:

  * hematologic toxicities
  * fatigue
  * mucositis
  * nausea/vomiting
  * diarrhea
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation)
* Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, uncontrolled congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements
* History of hypersensitivity reaction to capecitabine, 5-FU or any platinum containing drugs
* History of human immunodeficiency (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
* Evidence of concurrent second malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ
* Concurrent use of medications that inhibit cytochrome P450 3A4 (including aprepitant)
* History of bone marrow or major organ transplant